Thoracic Oncology
Clinical research activity is centered on advanced non-small-cell lung cancer, with attention to stage III/IV disease and patients with ROS1 gene rearrangement.
- Advanced NSCLC
- ROS1-rearranged lung cancer
- Thoracic malignancies
The sponsor’s research interest in this field reflects a focus on molecularly defined lung cancer populations managed in hospital-based oncology care.
Targeted Cancer Therapy
The funded study landscape includes treatment evaluation in oncogenic driver-positive cancer, with emphasis on therapies directed at ROS1-altered tumors.
- Driver mutation–selected therapy
- Molecular oncology
- Precision treatment for lung cancer
Research activity in this domain is aligned with treatment development for biomarker-defined malignancies in a specialized clinical setting.
Older and Frail Patient Oncology
The trial portfolio specifically addresses elderly patients and those with poor performance status, highlighting interest in cancer care for medically vulnerable populations.
- Geriatric oncology
- Frail patient populations
- Performance status–limited care
This area of interest supports clinical research tailored to patients who may have fewer treatment options because of age-related or functional limitations.
Oncology Response Assessment
Research activity includes evaluation of objective response rate and radiologic tumor response using RECIST v1.1 criteria, with independent review of treatment outcomes.
- Objective response rate
- Radiologic tumor assessment
- RECIST-based evaluation
These interests indicate a clinical focus on measurable antitumor activity in advanced lung cancer care.
